you are viewing a single comment's thread.
That would be the first validation of SGEN's ADC technology for solid tumors. T-DM1 would be the first validation of any ADC in solids.
I have not heard any financial terms. I suspect they are modest, but CDX-011 does have a large market potential so some "hard" value (in addition to validation as you mentioned).